|
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Clinical Trials Resources presented on Clinical Trials Search isn't meant to be a substitute for qualified health advice, visits or professional assistance with a real medical. We aren't doctors. Always consult your mD about Combination Chemotherapy in Treating Patients With Advanced Solid Tumors conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Clinical research trials and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors health trials occur in a lot of of places throughout the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically assess the effectivity of new does drugs. The role of the studies / projects is to resolve certain human healthcare questions. Clinical trials are a popular way for doctors, government agencies, and private sector corporations to detect remedies for all varieties of circumstances, such as Combination Chemotherapy in Treating Patients With Advanced Solid Tumors. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors Clinical Trials and other clinical trials allow volunteers to obtain health treatment choices before they are available to the general public. Most times the human subjects recieve professional assistance for free of charge, and every now and again they are paid for their time. Sometimes there is a cost for a Combination Chemotherapy in Treating Patients With Advanced Solid Tumors clinical trial. Human subjects frequently get the finest healthcare available for their Combination Chemotherapy in Treating Patients With Advanced Solid Tumors condition. Risks are a reality, however, and may include extra or frequent physician visits, medical dangers (possibly life-threatening), and/or the treatment being uneffective. Trials are federally governed with strict guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Combination Chemotherapy in Treating Patients With Advanced Solid Tumors  Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
For Condition: unspecified adult solid tumor, protocol specific
Status: No longer recruiting
Sponsor(s): Ireland Cancer Center , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of combination chemotherapy in treating patients who have advanced solid tumors.
Details: OBJECTIVES: - Determine the pharmacokinetic profile of gemcitabine, doxorubicin HCl liposome, and vinorelbine in patients with advanced solid tumors. - Determine the maximum tolerated dose of this regimen in these patients. - Determine the toxicity profile of this regimen in these patients. OUTLINE: This is a dose escalation study. Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1, gemcitabine IV over 30 minutes on days 1 and 8, and vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of doxorubicin HCl liposome, gemcitabine, and vinorelbine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose limiting toxicity. Patients are followed every 3 months for up to 1 year. PROJECTED ACCRUAL: Approximately 9-24 patients will be accrued for this study within 12-18 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed solid tumor not amenable to curative surgery, radiotherapy, or chemotherapy - No brain metastases or primary brain tumors PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - ECOG 0-2 Life expectancy: - At least 12 weeks Hematopoietic: - WBC at least 3,500/mm3 - Absolute neutrophil count at least 1,500/mm3 - Platelet count at least 100,000/mm3 - Hemoglobin greater than 10 g/dL Hepatic: - Bilirubin no greater than 1.2 mg/dL - AST and/or ALT less than 2.5 times upper limit of normal (ULN) - PT no greater than ULN (anticoagulant independent) Renal: - Creatinine no greater than 1.5 mg/dL AND/OR - Creatinine clearance greater than 60 mL/min Cardiovascular: - No New York Heart Association class III or IV heart disease - LVEF at least 45% by MUGA or echocardiogram Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior bone marrow or peripheral blood stem cell transplantation following high dose chemotherapy - At least 3 weeks since prior biologic therapy for cancer and recovered - No concurrent filgrastim (G-CSF) or sargramostim (GM-CSF) Chemotherapy: - See Disease Characteristics - See Biologic therapy - No more than 1 prior chemotherapy regimen - No prior vinca alkaloids - Prior anthracycline allowed if total dose no greater than 300 mg/m2 - At least 3 weeks since prior chemotherapy (6 weeks for mitomycin or carmustine) and recovered Endocrine therapy: - At least 3 weeks since prior endocrine therapy for cancer and recovered Radiotherapy: - See Disease Characteristics - No more than 1 prior radiotherapy regimen - At least 4 weeks since prior large field radiotherapy - At least 3 weeks since prior radiotherapy for cancer and recovered Surgery: - Not specified
Total Enrollment:
Location and Contact Information:
Overall Study Official:
BethOvermoyer, Study Chair, Ireland Cancer Center
Ireland Cancer Center
Cleveland, Ohio, 44106-5055
United States
Additional Information:
Study ID Numbers: CDR0000068245; NCI-G00-1859,CWRU-1Y99
Study Start Date:
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006372
Other Unspecified Adult Solid Tumor, Protocol Specific Studies:
1. Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
2. Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
3. Comparison of Antiemetic Drugs in Preventing Delayed Nausea After Chemotherapy in Patients With Cancer
4. Topotecan and Bortezomib in Treating Patients With Metastatic or Unresectable Cancer
5. BMS-247550 Plus Carboplatin in Treating Patients With Recurrent or Refractory Solid Tumors
Related Studies:
Other unspecified adult solid tumor, protocol specific Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Combination Chemotherapy in Treating Patients With Advanced Solid Tumors
|
|
|
|
|
|
|
|
